United Therapeutics insider files Form 144 for 4,000-share sale via TD Securities

Rhea-AI Filing Summary

United Therapeutics insider sale notice: This Form 144 reports that Martine Rothblatt proposes to sell 4,000 shares of United Therapeutics common stock through TD Securities on 09/26/2025 with an aggregate market value of $1,712,811.00. The filing shows these shares were acquired on 03/15/2016 as part of an executive deferred compensation arrangement totaling 294,000 shares and that payment was made by exercising vested options and delivering common shares. The filing also lists the insider's market sales over the past three months totaling 56,000 shares across multiple dates from 09/09/2025 to 09/25/2025, with daily gross proceeds shown per trade. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Positive

• Detailed compliance: The filing lists acquisition details, broker, planned sale date, and prior three months of sales, meeting Rule 144 disclosure requirements
• Transparency of consideration: Shows shares were acquired via executive deferred compensation on 03/15/2016 and payment via exercise/stock, clarifying source of shares
• Full sale history: Provides daily sale amounts and gross proceeds for trades from 09/09/2025 to 09/25/2025

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine compliance filing showing ongoing insider sales, no new company disclosures.

The Form 144 documents a proposed public sale of 4,000 common shares by Martine Rothblatt via TD Securities on 09/26/2025 valued at $1,712,811.00. The shares were acquired under an executive deferred compensation arrangement on 03/15/2016 (294,000 shares in that grant). The filing also transparently lists multiple sales totaling 56,000 shares executed between 09/09/2025 and 09/25/2025 with accompanying gross proceeds per trade. There are no financial results, forward guidance, or new operational disclosures in this notice; it functions as a regulatory disclosure of insider liquidity events.

Corporate Governance Expert

TL;DR: Properly completed Form 144 with full sale history; signals insider liquidity but includes required legal attestation.

The filing meets Rule 144 requirements by identifying acquisition date, nature of acquisition (executive deferred compensation), broker details (TD Securities), and a detailed list of sales over the prior three months. The seller attests to lack of undisclosed material adverse information. From a governance perspective, this is a standard disclosure of insider selling activity rather than a corporate action or governance change.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	4000	1712811.00	45230000	09/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672512.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736408.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/25/2025	4000	1723659.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for UTHR by Martine Rothblatt report?

The filing reports a proposed sale of 4,000 United Therapeutics common shares via TD Securities on 09/26/2025 with aggregate market value $1,712,811.00.

How were the shares being sold originally acquired?

The shares were acquired on 03/15/2016 under an executive deferred compensation arrangement; payment involved exercising vested options and delivering common shares.

How many shares did the insider sell in the past three months?

The filing lists sales totaling 56,000 shares executed between 09/09/2025 and 09/25/2025, with gross proceeds shown for each trade.

Who is acting as broker for the proposed sale?

The broker named in the notice is TD Securities (USA) LLC, located at 125 Park Ave, 20th Floor, New York, NY 10017.

Does the Form 144 include any statements about undisclosed material information?

Yes, the filer signs an attestation representing that they do not know any material adverse information about the issuer that has not been publicly disclosed.